
01
Developing and diversifying respite structures
02
Consolidating rights and training for carers
03
Improving health monitoring for family carers
04
Quality labelling throughout the country for "single points of contact", the "Maisons pour l’Autonomie et l’Intégration des malades Alzheimer" (MAIA)
05
Establishing "coordinators" throughout the country
06
Reinforcing support at home, advocating services by trained staff
07
Improving support at home using new technologies
08
Preparing and implementing a system for giving the diagnosis and providing counselling
09
Experimenting new payment terms for health professionals
10
Creating an Alzheimer’s disease information card for each patient
11
Creating memory units in areas that are not covered
12
Creating "memory resource and research centres" in areas that are not covered
13
Reinforcing the very active memory units
14
Monitoring drug-related iatrogenic accidents
15
Improving correct use of drugs
16
Creating specific units for patients suffering from behavioural problems within EHPADs
17
Creating specialized units within health care rehabilitation and follow-up (SSR) departments for Alzheimer’s patients
18
Accommodation for young patients
19
Identifying a national reference centre for young Alzheimer’s patients
20
A specific career and skills development plan for Alzheimer’s disease
21
Creating a foundation for scientific cooperation to stimulate and coordinate scientific research
22
Developing clinical research of Alzheimer’s disease and improving evaluation of non-drug therapies
23
Doctoral and post-doctoral grants
24
New assistant surgeon and hospital teaching assistant positions
25
Research in human and social sciences
26
Support for research groups working on innovative approaches
27
Support for methodological research groups in human and social sciences
28
Creation of a body of research in automatic image processing
29
Studying large patient populations (cohorts) with long-term monitoring
30
High-speed genotyping
31
Exploiting the genome sequencing of the microcebe
32
Training in clinical epidemiology
33
Developing links between public research and industry
34
Setting up epidemiological surveillance and follow up
35
Setting up a telephone helpline and a website for information and local advice
36
Holding regional conferences to support the implementation of the plan
37
Studying disease knowledge and attitudes
38
Creating a space for ethical thought about Alzheimer’s disease
39
Launching a discussion about the legal status of Alzheimer’s patients in institutions
40
Organising regular meetings focusing on the autonomy of people suffering from Alzheimer’s disease
41
Informing patients and their families about trials implemented in France
42
Making the fight against Alzheimer’s disease a priority for the European Union during the French presidency
43
Publicizing and promoting research across Europe
44
Holding a European conference in autumn 2008
45
Studying opinion and attitude about Alzheimer’s disease and the impact of the plan among patients and carers
A new measure for the Alzheimer’s plan : when setting the plan’s governance early 2008 and defining proper assessment for each measure of the plan, it appeared necessary to study opinion and attitude about the disease and the impact of the plan among patients and their carers.
The first results of measure 37, “studying disease knowledge and attitudes”, helped to define precisely the measure.
Firstly, INPES (Institut national de prévention et d’éducation pour la santé, the National Institute for Prevention and Health Education) reviewed literature on social representation of Alzheimer’s disease. This study reviewed 15 years and analysed scientific publications from France and the whole world. It confirmed that perception of Alzheimer’s disease throughout the world is extremely negative, with slight differences between general public and those more concerned with the disease.
In order to review the public‘s awareness, knowledge and attitudes about Alzheimer’s disease, the INPES asked IPSOS to carry a qualitative survey on a hundred persons from public, family carers and health professionals. Carried during summer 2008, this study showed that fear and shame are attached to Alzheimer’s disease which is considered as a true disaster. It also revealed very fragmented knowledge on Alzheimer’s disease from those who were asked, including family carers and health professionals. On the other hand, expectations are great among general population concerning research, institutions and training.
Measure 37 also plans to incorporate a module of questions on Alzheimer’s disease into the INPES health survey addressed to general practitioners.
Adding to measure 37, « studying knowledge and attitudes »,
Series of quantitative studies, on larger samples than those from the qualitative study in measure 37 will be carried on different populations :
These studies will be carried again in 2011 in order to assess the evolution of their attitudes toward Alzheimer’s disease and to estimate their knowledge and opinion on some measures of the Alzheimer’s plan.
Supervisor : INPES (Institut national de prévention et d’éducation pour la santé, national institute for prevention and health education)
Partners : the directorate general for health (direction générale de la santé, DGS), the Directorate General for Social Action (Direction générale de l’action sociale, DGAS), the National Independent-Living Support Fund (Caisse nationale de solidarité pour l’autonomie des personnes âgées et des personnes handicapées, CNSA), the sanitary survey institute (InVS, institut de veille sanitaire, Bordeaux School of Public Health (Institut de Santé Publique, d’Épidémiologie et de Développement, Isped Bordeaux), association France-Alzheimer, Pfizer, FCS, Foundation Médéric Alzheimer
October 2008- september 2009 for the first series of surveys.
2011 for the second.
INPES :
2008-2009 :
- Quantitative study on general public : 65 000 €
- Qualitative study on patients : 20 000 €
- Quantitative study on family carers : 50 000 €
- Quantitative study on health professionals : 80 000 €
- Quantitative study on patients : 50 000 €
Other measures of the plan will be assessed with results from this measure.